Other languages MaxCyte, Inc.

Equities

MXCT

US57777K1060

Delayed London S.E. Other stock markets 03:00:21 2024-04-30 am EDT			5-day change	1st Jan Change
291.1 ^GBX	-1.32%		-9.88%	-17.42%

Apr. 02	MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines	CI
Mar. 13	BTIG Adjusts Price Target on MaxCyte to $8 From $10, Maintains Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MaxCyte inks deal with Be Bio; Orcadian firms farmout	Apr. 02
MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines	Apr. 02
MaxCyte loss widens in 2023 as core revenue declines 25%	Mar. 13
MaxCyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12
MaxCyte, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 12
MaxCyte, Inc. Reiterates Earnings Guidance for the Year 2024	Mar. 12
EARNINGS: dotdigital eyes rosy future; Beeks Financial turns to profit	Mar. 05
MaxCyte Reaffirms Fiscal 2023 Revenue Guidance	Mar. 04
MaxCyte, Inc. Provides Revenue Guidance for the Fiscal Year 2023 and 2024	Mar. 04
MaxCyte, Wugen Enter Platform License Deal	Jan. 30
MaxCyte signs licencing deal with cell therapy company Wugen	Jan. 30
MaxCyte, Inc. and Wugen, Inc. Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen's Investigational Allogeneic, Off-The-Shelf Cell Therapies for Cancers	Jan. 30
MaxCyte chief scientific officer leaves firm	Jan. 29
MaxCyte, Inc. Announces Departure of Cenk Sumen as Chief Scientific Officer	Jan. 26
Esken's Southend Airport faces further allegations	Jan. 23
MaxCyte Inks Platform License Deal With Cancer Medicine Developer Imugene	Jan. 23
MaxCyte, Inc. Signs Strategic Platform License with Imugene to Advance Their Cancer Immunotherapy Programs	Jan. 23
MaxCyte's strategic platform licences redeem otherwise modest results	Jan. 09
MaxCyte Reports Preliminary Q4 Revenue; Shares Rise After Hours	Jan. 08
MaxCyte, Inc. Provides Preliminary Financial Guidance for the Fourth Quarter and Full Year Ended December 31, 2023	Jan. 08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages MaxCyte, Inc.

Equities

MXCT

US57777K1060

Other languages

Filters